Kirk N. Campbell, MD
C. Mahlon Kline Professor
Attending Physician, Division of Renal, Electrolyte, and Hypertension, Hospital of the University of Pennsylvania
Chief, Division of Renal, Electrolyte, and Hypertension, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Department of Medicine
Division of Renal, Electrolyte, and Hypertension
3400 Spruce Street
1 Founders, Renal Suite
Philadelphia, PA 19104
Division of Renal, Electrolyte, and Hypertension
3400 Spruce Street
1 Founders, Renal Suite
Philadelphia, PA 19104
Education
BS (Biochemistry--Magna cum laude)
City College of the City University of New York, New York, NY, 1996.
MD (Medicine)
University of Connecticut, Farmington, CT, 2000.
Permanent linkBS (Biochemistry--Magna cum laude)
City College of the City University of New York, New York, NY, 1996.
MD (Medicine)
University of Connecticut, Farmington, CT, 2000.
Description of Clinical Expertise
My clinical interest is in glomerular disease with a particular focus on IgA nephropathy and podocytopathies including focal segmental glomerulosclerosis (FSGS) and minimal change disease.Description of Research Expertise
Dr. Campbell leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease and clinical trials in the rare kidney disease space. The projects center on advancing the understanding of the underlying mechanisms involved in glomerular disease progression while identifying targets for therapeutic intervention. The work has resulted in two patents and support from a Harrington Discovery Institute Scholar-Innovator Award, He has been a lead principal investigator, steering committee chair and data safety monitoring committee member for multiple clinical trials testing novel agents for FSGS, IgA nephropathy, lupus nephritis and membranous nephropathy. He is an elected member of the American Society for Clinical Investigation and a member of the Editorial Boards of Kidney360, Kidney International, American Journal of Kidney Disease, Frontiers in Medicine and the American Journal of Physiology – Renal Physiology.Selected Publications
Mohandes S, Nast CC, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Ellis C, Bansal S, Argyropoulos C, Jennette JC, Gasim A, Stillman IE, Campbell KN, Abedini A, Coppock G; TRIDENT Consortium; Susztak K, Palmer MB.: Improving the Histologic Classification of Advanced Diabetic Nephropathy Based on the Transformative Research in Diabetic Nephropathy (TRIDENT) Findings. Kidney Int Aug 2026.Mohandes S, Fakhreddine M, Sheng H, Al Dulaimee M, Mottl A, Scialla J, Almaani S, Luciano R, Isakova T, Bansal S, Argyropoulos C, Avasare R, Singh M, Campbell KN, Townsend R, Coppock G, Palmer M, Susztak K; TRIDENT Consortium.: Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort. Clin J Am Soc Nephrol 21: 1376-1385, Aug 2026.
Heerspink HJL, Arnott C, Barratt J, Campbell KN, Pecoits-Filho R, Fukami K, Halimi JM, Hou FF, Lam CSP, Levin A, Lindberg M, Kashioulis P, Mercier AK, Sinsakul M, Ambery P, Perkovic V.: Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD. Nephrol Dial Transplant Aug 2026.
Vasquez-Rios G, Chauhan K, Naik N, Pattharanitima P, Chan L, Campbell KN, Nadkarni GN, Coca SG.: Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-Risk APOL1 Genotypes. medRxiv Jun 2026.
Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J; ORIGIN Phase 3 Trial Investigators.: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N Engl J Med 394: 647-657, Feb 2026.
Floege J, Ayoub I, Brix SR, Campbell KN, Furie R, Nachman PH, Tang SCW, Tomas NM, Vivarelli M, Cheung M, King JM, Grams ME, Jadoul M, Rovin BH; Conference Participants.: Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2026.
Fischman CJ, Zee J, Campbell KN.: Family Matters: Dissecting the Impact of Family Medical History, APOL1 Genotype, and Sociodemographic Factors on CKD Progression in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2026.
Yu L, Ekperikpe US, Korsmo HW, Zhao S, Yi Z, Haydak J, Lefferts S, Meliambro K, Campbell KN, Azeloglu EU, Kohan DE, McCown PJ, Naik AS, Otto EA, Haraldsson B, Zhang W, Daehn IS.: Podocyte-derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis. Kidney Int 2026.
Wong JS, Campbell KN.: Communication leading to injury: podocyte-derived fibrillin-1 induces mesangial cell activation and proliferation through EGFR signaling. Kidney Int 2026.
Sanchez-Russo L, Vasquez-Rios G, Campbell KN.: Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition. Am J Kidney Dis 2026.